Related Experiment Videos
Therapeutic targets in cardiovascular disease: a case for high-density lipoprotein cholesterol
1Merck & Company, Inc., Rahway, New Jersey 07065, USA. donald_black@merck.com
The American Journal of Cardiology
|April 8, 2003
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.
European heart journal·2022
Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.
Journal of cardiovascular pharmacology·2021
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.
Circulation. Genomic and precision medicine·2021
Outcomes After Percutaneous Transcatheter Release Or Fibrinolysis For Obstructive Mechanical Mitral Valve Thrombosis.
The American journal of cardiology·2026
Mitral Annular Calcification as a Marker of the HFpEF Phenotype: The Interplay of Cardiac Remodeling, Age, and Sex.
The American journal of cardiology·2026